stockmarketproxy
/
MDGLNasdaqSEC EDGAREDGAR

MADRIGAL PHARMACEUTICALS, INC.

Pharmaceutical Preparations·WEST CONSHOHOCKEN, PA·FY end 12/31·CIK 1157601
OverviewFinancialsCompensationGovernanceInsidersFilings

Financials

5-year history · USD
MetricFY 2025FY 2024FY 2023FY 2022FY 2021Trend
Revenue$958.4M$180.1M———
Gross Profit——————
Operating Income-$300.1M-$497.9M-$117.2M-$85.3M-$64.6M
Net Income-$288.3M-$465.9M-$112.2M-$85.9M-$64.5M
Operating CF-$189.6M-$455.6M-$324.2M-$224.9M-$183.9M
Capex$467.0K$1.5M$1.5M$217.0K$209.0K
Free Cash Flow-$190.0M-$457.0M-$325.7M-$225.1M-$184.1M
Buybacks——————
Dividends——————
Gross Margin——————
Operating Margin-31.3%-276.4%———
Net Margin-30.1%-258.6%———
FCF Margin-19.8%-253.7%———
R&D / Revenue——————
Effective Tax——————
Debt / Equity1.130.310.570.60—
Buybacks / FCF——————

Peer comparison

Pharmaceutical Preparations · 5 peers
CEO Pay Ratio
MDGL
47:1
ROIV
518:1
AXSM
23:1
JNJ
—
COGT
95:1
PFE
277:1
CEO total comp
MDGL
$19M
ROIV
$163M
AXSM
$34M
JNJ
$33M
COGT
$28M
PFE
$28M
Net Margin
MDGL
-30.1%
ROIV
-592.0%
AXSM
-28.7%
JNJ
28.5%
COGT
—
PFE
12.4%